A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008204/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability,
pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with
MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists
of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or
metastatic NSCLC subjects
提供机构：
Vivli
创建时间：
2022-07-06
